Brokerages Set enGene Holdings Inc. (NASDAQ:ENGN) Target Price at $11.05

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have earned an average recommendation of “Hold” from the fourteen brokerages that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $11.0455.

A number of research firms have weighed in on ENGN. UBS Group decreased their price objective on shares of enGene from $9.00 to $2.00 and set a “neutral” rating for the company in a research report on Thursday, May 14th. Citigroup cut enGene from a “market outperform” rating to a “market perform” rating in a research note on Friday, May 8th. Guggenheim cut enGene from a “buy” rating to a “neutral” rating in a research note on Thursday, May 7th. Wall Street Zen upgraded enGene from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Citizens Jmp downgraded enGene from an “outperform” rating to a “market perform” rating in a report on Friday, May 8th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Millennium Management LLC increased its position in shares of enGene by 57.3% in the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after purchasing an additional 7,472 shares during the last quarter. Raymond James Financial Inc. lifted its position in shares of enGene by 383.6% during the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after purchasing an additional 7,932 shares during the last quarter. Cresset Asset Management LLC acquired a new position in enGene in the second quarter worth about $36,000. Paloma Partners Management Co acquired a new position in enGene in the second quarter worth about $38,000. Finally, Jump Financial LLC bought a new stake in enGene in the fourth quarter valued at about $121,000. 64.16% of the stock is currently owned by institutional investors.

enGene Trading Down 4.5%

NASDAQ ENGN opened at $1.82 on Friday. The stock has a market cap of $122.25 million, a P/E ratio of -0.84 and a beta of -0.28. The company’s fifty day simple moving average is $1.81 and its 200-day simple moving average is $4.49. The company has a current ratio of 12.57, a quick ratio of 12.57 and a debt-to-equity ratio of 0.10. enGene has a 52 week low of $1.40 and a 52 week high of $12.25.

enGene (NASDAQ:ENGN) last released its quarterly earnings results on Monday, June 15th. The company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.05. During the same quarter last year, the business earned $0.51 EPS. Equities research analysts predict that enGene will post -1.84 EPS for the current fiscal year.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.